Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Eyes Tianjin Tianyao Pharmaceuticals For Acquisition

This article was originally published in PharmAsia News

Executive Summary

According to sources, world's top steroid producer Pfizer plans to acquire number three rival Tianjin Tianyao Pharmaceuticals to further reinforce its number one position. Eying the lucrative steroid pie, which expands 11.8 percent annually in China, Pfizer is making overtures of alliance to Tianyao. Although Pfizer denies the news, many industry insiders confirm that both parties have held preliminary discussion. However, Pfizer faces a challenge in getting the nod from Tianjin Municipal Commission of State-owned Assets Supervision to acquire state-owned Tianyao. In addition, the deal needs to surmount the anti-trust judgment from China's Ministry of Commerce since the merger could result in domestic monopoly of steroid supply. (Click here for more - Chinese Language)

You may also be interested in...

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts